Lymphocyte

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Retrieved on: 
måndag, juni 3, 2024
PD-1, Lymphocyte, IND, Patient, Trial of the century, SAN, Clinical trial, CCR8, NK, Investigational New Drug, Food, FDA, Regeneron Pharmaceuticals, Pharmaceutical industry

“We are very excited to collaborate with Regeneron Pharmaceuticals to evaluate two separate novel combination approaches to treat patients with select solid tumors,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.

Key Points: 
  • “We are very excited to collaborate with Regeneron Pharmaceuticals to evaluate two separate novel combination approaches to treat patients with select solid tumors,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • “We believe that the mechanisms of action for both FG-3165 (anti-Gal9) and FG-3175 (anti-CCR8) have the potential to be synergistic with cemiplimab, providing the possibility for an improvement in clinical outcomes for patients.
  • Under the clinical study collaboration and supply agreement, Regeneron will provide drug supply to FibroGen, who will be the sponsor of each Phase 1 monotherapy and combination trial.
  • Each company retains all rights to their respective compounds, including as a monotherapy or as combination therapies.

1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China

Retrieved on: 
tisdag, maj 28, 2024
Infection, Patient, Hospital, NMPA, Laboratory, Safety, Cancer, Lymphocyte, Full Spectrum, Immunodeficiency

This is the first clinical 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling™ (FSP™) capability.

Key Points: 
  • This is the first clinical 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling™ (FSP™) capability.
  • Clinical TBNK analysis is routinely used to assess and monitor immune system status for various medical conditions, with TBNK reagents enabling the identification and quantification of key lymphocyte subsets.
  • By providing insight into the immune system's composition, function, and therapeutic response, TBNK reagents support targeted treatment decisions and ongoing patient management.
  • Cytek continues to seek regulatory approvals in additional geographies to provide its cell analysis solutions for clinical use more broadly.

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

Retrieved on: 
tisdag, maj 28, 2024
Merck & Co., Interleukin, Patient, Survival, Lymphocyte, Pembrolizumab, Ovarian cancer, Immune system, Neoplasm, PFS, TILT, Safety, RECIST, Assistant, Cancer, Potyvirus, ASCO, Merck, Health Affairs, Abstract, OS, Society, Pharmaceutical industry

HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
  • Abstract (5562) demonstrates promising safety and efficacy data of TILT-123 in ovarian cancer patients, whilst abstract (2658) demonstrates the potential for TILT-123 as an intravenous therapy.
  • 14 patients (out of 15 enrolled) were evaluable for treatment response, with disease control achieved in 64.3%.
  • This means TILT-123 reached tumors, despite not being directly injected into them, and successfully triggered an immune system toward the cancer.

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
måndag, maj 20, 2024
Patient, DDW, Inflammation, Doctor of Philosophy, BOCA, Lymphocyte, Clinical trial, Diagnosis, Coeliac disease, Therapy, Health, Conference, Database, Serology, Research, IEL, Poster, Diet, CED, Management

BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.

Key Points: 
  • BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.
  • The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
  • “These findings will enable us to better monitor celiac disease and refine the tools we use in its diagnosis,” said Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics.
  • President & Chief Scientific Officer, Entero Therapeutics; Jennifer Sealy-Voyksner, PhD., Vice President R&D, Entero Therapeutics

Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Other Health, Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Science, Health, Patient, Doctor of Philosophy, CPI, The Cancer Genome Atlas, Survival, Lymphocyte, TIL, Data, TILS, Translational medicine, TME, IPS, Tumor microenvironment, Lung cancer, Therapy, PFS, Senior, AI, Neoplasm, IIP, IP, Biomarker, ASCO, Society, Classification, Haematoxylin, Dip, TCGA, Annual general meeting

Incendia Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present data in collaboration with PathAI, a leading AI-powered precision pathology company at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • Incendia Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present data in collaboration with PathAI, a leading AI-powered precision pathology company at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, Illinois.
  • “The data demonstrate the correlation between immune phenotypes predicted from hematoxylin and eosin (H&E)-stained whole slide images and survival following checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC).
  • In the clinical cohort, cancer tumor infiltrating lymphocytes density and fraction of hot epithelial patches were significantly associated with (PFS) (HR=0.64, q=0.04 and HR=0.69, q=0.04, respectively).
  • Notably, in PD-L1(-) patients (N=43, tumor proportion score ≤1%), iIP patients had longer PFS than eIP and dIP patients (HR=0.35, p=0.02).

Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Patient, Steroid, Pulmonary edema, Lymphocyte, Renal cell carcinoma, PD, Bladder cancer, Colorectal cancer, Clinical trial, CDT, Lung cancer, Head, Serum, NSCLC, Hypertelorism, Lymphocytopenia, Blood, Neoplasm, Avelumab, IL-2, Melanoma, MSI, ASCO, CD25, Poster, IL-6, Society, Artificial intelligence, Therapy, Hand, PD-L1, ADAS, Annual general meeting, MSS, CRS, RCC, Medical imaging

The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.

Key Points: 
  • The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.
  • The durability of the tumor reductions seen in several patients suggests the formation of immune memory of the cancerous cells.
  • “While other developmental IL-2 therapies focus on changing IL-2 itself, AU-007 is a human antibody that is a well-established therapeutic modality.
  • The Phase 2 expansion cohorts of the AU-007 study are continuing to enroll patients with a focus on melanoma and RCC.

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Retrieved on: 
torsdag, maj 9, 2024
CD33, Patient, Phenotype, AML, Administration, Transplant, Research and development, Bone marrow, Acute myeloid leukemia, Lymphocyte, Clinical trial, MDS, G&A

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the first quarter of 2024 were $24.3 million, compared to $21.9 million for the first quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses for the first quarter of 2024 were $8.0 million, compared to $8.5 million for the first quarter of 2023.
  • Net Loss: Net loss for the first quarter of 2024 was $30.8 million, compared to $28.4 million for the first quarter of 2023.

Pharming Group reports first quarter 2024 financial results and provides business update

Retrieved on: 
onsdag, maj 8, 2024
VWAP, VUS, FDA, Phase, Haploinsufficiency, IRP, Iberian languages, Laboratory, Safety, Euronext Amsterdam, Pharmacokinetics, PTEN, Epidemiology, CTLA4, Marketing, World Games, APDS, Health care, MAA, CHMP, Trial of the century, Genetic testing, Disease, Patient, Physician, EMA, Primary immunodeficiency, Ministry, Variant, Committee, MHRA, Diagnosis, Pids, PID, Lymphocyte, Clinical trial, Government, Microsoft Access, Prevalence, Ageing, Pharmaceutical industry

“Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million.

Key Points: 
  • “Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million.
  • Pharming made continued progress in the first quarter of 2024 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.
  • Pharming announced completion of enrollment in the clinical trial for children ages 4 to 11 years old on April 8, 2024.

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
tisdag, maj 7, 2024
Birth, FDA, Capsule, Myelokathexis, Research and development, Priority review, Safety, WHIM syndrome, Food, Security (finance), Conference call, WHIM, Research, Conference, Wart, Neutrophil, CIS, Patient, Society, EMA, Hypogammaglobulinemia, Infection, G-CSF, Interim, Immune system, Lymphocyte, Clinical trial, ID, European Medicines Agency, Pharmaceutical industry

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and highlighted key recent and upcoming expected milestones.
  • “Concurrent with this approval, we received a Rare Pediatric Disease Priority Review Voucher, which we intend to monetize.
  • X4 currently expects to seek approval from the European Medicines Agency (EMA) for mavorixafor in WHIM syndrome in late 2024/early 2025.
  • The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com.

EQS-News: Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium

Retrieved on: 
fredag, maj 3, 2024
Cancer, Safety, Blood, Immunosuppression, Intensive care medicine, Pain management, Patient, Teaching hospital, Lymphocyte, IBS, Medical device

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.

Key Points: 
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
  • The symposium will take place in Bologna, Italy between April 18 – 20, 2024.
  • CATUVAB® aims to ensure that cancer patients receive their own blood, minimizing the risks associated with allogenic (donor) blood transfusions.
  • Following the positive study outcome, CATUVAB® is aimed for approval in the EU and US in accordance with Medical Device Regulations.